EGFR and lung cancer: EGFR resistance frequently occurs after 8–16 months when EGFR tyrosine kinase inhibitors like erlotinib and afatinib are utilized.561 Addressing drug-resistant lung cancer poses a significant obstacle in the realm of lung cancer treatment.